Repligen Q3 2025 Earnings Preview
This article provides an earnings preview for Repligen's Q3 2025 financial results. Investors are anticipating the report to assess the company's performance and future outlook.
Are options traders betting on a big move in Repligen stock?
This article analyzes unusual options activity for Repligen (RGEN), suggesting that significant trading volume in specific call and put options could indicate expectations of a large price movement in the near future. It calculates the implied volatility and analyzes the strike prices to infer potential bullish or bearish sentiment among options traders.
Are Options Investors Anticipating Significant Movement in Repligen Shares?
Options traders are showing significant interest in Repligen Corporation (RGEN), particularly the May 15, 2026 $70 Call option, due to exceptionally high implied volatility. This suggests market anticipation of substantial price movement, potentially signaling an upcoming event. Despite this, analysts have a "Hold" rating for Repligen, with one recent earnings forecast raise, indicating a possible trading opportunity for experienced options traders.
Are Options Investors Anticipating Significant Movement in Repligen Shares?
Options traders are showing significant interest in Repligen Corporation (RGEN), particularly regarding the May 15, 2026 $70 Call option, which exhibits high implied volatility. This suggests market anticipation of substantial price movement in the stock. Despite a recent analyst downgrade of earnings forecasts, the high implied volatility might indicate a potential trading opportunity for skilled options traders.
(RGEN) Price Dynamics and Execution-Aware Positioning
This article provides an AI-driven analysis of Repligen Corporation (NASDAQ: RGEN), highlighting weak near and mid-term sentiment despite a positive long-term outlook. It identifies elevated downside risk and offers three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored to different risk profiles. The analysis also includes multi-timeframe signal analysis for support and resistance levels.
Repligen Corp (RGEN) Stock Price Quote Today & Current Price Chart
The article provides a stock price quote and current price chart for Repligen Corp (RGEN). It suggests using the Capital.com smart investment app for online trading.
Repligen Corp (RGEN) Stock Price Quote Today & Current Price Chart
This article provides the current stock price quote and chart for Repligen Corp (RGEN), detailing its intraday performance, current price, high, and low. It also outlines key trading conditions for RGEN CFDs, including spreads, overnight funding adjustments, margin requirements, and commission, alongside offering related market news and customer reviews for the trading platform.
Repligen Corp Stock: Bioprocessing Leader with Strong Growth in Biopharma Supply Chain
Repligen Corp is a key player in the bioprocessing sector, providing essential technologies for the manufacturing of biologics, including cell and gene therapies. The company's core business model focuses on proprietary consumables and systems, generating recurring revenue, primarily driven by North American biopharma demand. Investors are interested in Repligen for its exposure to biopharma infrastructure without direct drug development risks, supported by its strong financial health and strategic positioning in an expanding market.
Repligen Corp (RGEN) Stock Price Quote Today & Current Price Chart
This article provides a real-time stock price quote and current price chart for Repligen Corp (RGEN). It also mentions an online trading platform.
Vanguard amends Schedule 13G/A for Repligen (RGEN): reports 0 shares
The Vanguard Group filed an Amendment No. 7 to Schedule 13G/A for Repligen Corp (RGEN), reporting no beneficial ownership of the common stock. This filing indicates 0 shares beneficially owned, representing 0% of the class, and zero voting and dispositive power. The change is due to an internal realignment on January 12, 2026, where certain Vanguard subsidiaries will now report ownership separately.
Riverbridge Partners LLC Sells 30,070 Shares of Repligen Corporation $RGEN
Riverbridge Partners LLC has reduced its stake in Repligen Corporation by 8.8%, selling 30,070 shares and retaining 313,365 shares valued at $51.35 million. Despite this sale, institutional ownership remains high at 97.64%, and analysts maintain a "Moderate Buy" rating with a target price of $176.92. Repligen also reported strong quarterly earnings, beating expectations with $0.49 EPS and an 18.1% year-over-year revenue increase while setting positive FY2026 EPS guidance.
RGEN PE Ratio & Valuation, Is RGEN Overvalued
Repligen Corp (RGEN) is currently in the "Fair zone" according to its forward PE ratio of 85.23, which is fairly comparable to its five-year average. The relative valuation method suggests a fair price for RGEN between $87.64 and $129.59. While RGEN's P/S ratio is slightly above the industry average, its strong revenue growth of 18.12% may make this premium unsustainable.
Repligen Corporation $RGEN Stock Position Raised by Congress Asset Management Co.
Congress Asset Management Co. significantly increased its stake in Repligen Corporation (NASDAQ:RGEN) by 241.4% in the fourth quarter, now owning 1.33% of the company's stock valued at $122.29 million. Several other institutional investors also adjusted their positions in RGEN, and the stock currently has an average rating of "Moderate Buy" with a consensus price target of $176.92. Repligen recently reported strong quarterly earnings, beating analyst estimates for both EPS and revenue.
E. Ohman J or Asset Management AB Takes Position in Repligen Corporation $RGEN
E. Ohman J or Asset Management AB has acquired a new stake of 33,689 shares in Repligen Corporation (NASDAQ:RGEN) during Q4, valued at approximately $5.52 million. This move comes despite recent target price cuts from some analysts, though the consensus remains a "Moderate Buy" with an average price target of $176.92. Repligen also reported strong Q4 earnings, beating expectations, and provided positive FY2026 guidance.
Repligen (NASDAQ: RGEN) COO granted options and 7,751 RSUs
Repligen Corporation's COO, James Bylund, was granted 8,315 stock options with an exercise price of $141.91 and 7,751 restricted stock units (RSUs). The stock options vest in three equal annual installments starting March 5, 2027, and expire on March 5, 2036. The RSUs also vest in equal annual installments over three years from the grant date, and each RSU represents one share of common stock. Following these grants, Mr. Bylund directly holds 25,423 common stock shares.
Repligen (RGEN) SVP R&D Ralf Kuriyel receives new stock options and RSUs
Ralf Kuriyel, Senior VP of R&D at Repligen Corporation (RGEN), has been granted new equity awards including 5,669 stock options and 5,284 restricted stock units. The stock options have an exercise price of $141.91 and vest in equal annual installments over three years starting March 5, 2027, while the restricted stock units also vest in equal annual installments over three years from the grant date. Following these grants, Kuriyel's direct holdings in Repligen Common Stock increased to 20,062 shares.
Repligen (RGEN) CEO receives 25,890 options and 24,134 RSUs
Repligen Corporation's CEO, Olivier Loeillot, was granted 25,890 stock options with an exercise price of $141.91 and 24,134 restricted stock units. These new equity awards increase his direct ownership to 58,078 shares of Common Stock. The options and RSUs will vest over three years, with the options expiring in 2036.
H.C. Wainwright raises Repligen stock price target on strong growth
H.C. Wainwright has increased its price target for Repligen (NASDAQ:RGEN) to $208 from $180, maintaining a Buy rating due to the bioprocessing company's strong operating results. Repligen achieved 14% organic growth in fiscal year 2025, exceeding guidance, and expanded its portfolio and global footprint. The company provided optimistic revenue guidance for full-year 2026, leading to a revised forecast from H.C. Wainwright.
RGEN: HC Wainwright & Co. Raises Price Target for Repligen | RGE
HC Wainwright & Co. has raised its price target for Repligen (RGEN) to $208.00 from $180.00, maintaining a "Buy" rating. This positive adjustment comes amid recent downward revisions by other analysts. The company, a global life sciences firm specializing in bioprocessing equipment, has an average target price of $186.95 from 17 analysts, implying a significant upside from its current price.
Hudson Bay Capital Management LP Invests $2.81 Million in Repligen Corporation $RGEN
Hudson Bay Capital Management LP has initiated a new position in Repligen Corporation, purchasing 21,003 shares valued at approximately $2.81 million in the third quarter. Repligen exceeded quarterly earnings and revenue expectations, and analysts generally maintain a "Moderate Buy" rating for the stock. Despite some price target adjustments and a downgrade from one firm, institutional ownership of Repligen remains high.
Repligen Conference: CEO touts differentiated bioprocessing portfolio; CFO targets 30% EBITDA margin
Repligen's CEO highlighted the company's differentiated bioprocessing portfolio, with 80% of products offering unique solutions, and emphasized commercial momentum through bundled offerings and deeper penetration into large accounts. The CFO outlined an ambitious goal of achieving a 30% EBITDA margin and 25%+ EBIT margin by 2030, leveraging pricing, volume, and operational efficiencies. Despite some near-term industry headwinds, management remains optimistic about future growth driven by innovation and strategic market positioning.
Covea Finance Invests $4.59 Million in Repligen Corporation $RGEN
Covea Finance has acquired a new position of 28,000 shares in Repligen Corporation (NASDAQ:RGEN), valued at approximately $4.59 million. This investment comes as Repligen reported strong Q4 results, exceeding revenue and EPS expectations, and provided optimistic FY2026 guidance. Despite some recent analyst downgrades, institutional ownership remains high, and the stock currently holds a "Moderate Buy" rating with an average target price of $174.58.
Repligen Corp stock drops 3.17% on NASDAQ amid biotech sector pressures and upcoming earnings
Repligen Corp (RGEN) stock dropped 3.17% on NASDAQ, closing at $113.88 USD on March 20, 2026, amid broader biotech sector pressures and anticipation of upcoming Q3 2025 earnings. The decline, despite the company's strong fundamentals in bioprocessing and analyst upgrades, highlights sector volatility. DACH investors are advised to consider the company's long-term potential in biomanufacturing while monitoring earnings and sector trends.
(RGEN) as a Liquidity Pulse for Institutional Tactics
This article provides an AI-driven analysis of Repligen Corporation (NASDAQ: RGEN), highlighting near-term positive sentiment, mid-term weak bias, and long-term strength. It outlines institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels. The report emphasizes the current price positioning and elevated downside risk.
Repligen targets 10% to 15% growth in proteins for 2025 following new resin launches
The article discusses Repligen's projected growth in its proteins business. The company is targeting 10% to 15% growth for 2025, driven significantly by recent launches of new resins.
Repligen targets 10% to 15% growth in proteins for 2025 following new resin launches
Repligen is projecting a significant growth of 10% to 15% in its protein segment for 2025, driven by the anticipated launch of new NGL series resins later this year. This expansion, particularly in the biologics and gene therapy markets, also includes the opening of a new ligand manufacturing facility. The company is strategically positioning itself to capitalize on increasing demand for protein-based therapies.
Repligen Q4 2025 earnings preview
This article is a preview of Repligen's Q4 2025 earnings. It is likely to cover expectations for the company's financial performance during that quarter. However, the provided content is empty, so no further details can be extracted.
Alliancebernstein L.P. Buys 197,778 Shares of Repligen Corporation $RGEN
Alliancebernstein L.P. has increased its stake in Repligen Corporation (NASDAQ:RGEN) by 21.8% during the third quarter, acquiring an additional 197,778 shares to own a total of 1,104,171 shares valued at $147.6 million. Other institutional investors have also adjusted their holdings in the biotechnology company. Repligen recently reported strong quarterly earnings, exceeding analyst expectations, and has received a "Moderate Buy" consensus rating from analysts with an average target price of $174.58.
270,000 Shares in Repligen Corporation $RGEN Acquired by Iron Triangle Partners LP
Iron Triangle Partners LP significantly increased its stake in Repligen Corporation (NASDAQ:RGEN) during Q3 2025, acquiring 270,000 shares valued at approximately $36.09 million. This move, along with substantial investments from other institutional firms, pushed institutional ownership to nearly 97.64%, reflecting robust institutional confidence. Despite recent price target adjustments by analysts, Repligen maintains a "Moderate Buy" consensus rating and recently surpassed quarterly earnings estimates.
Holocene Advisors LP Boosts Stock Position in Repligen Corporation $RGEN
Holocene Advisors LP significantly increased its stake in Repligen Corporation (NASDAQ:RGEN) by 47.0% in Q3, now owning 1,377,104 shares valued at approximately $184.1 million. Other institutional investors also adjusted their positions. Repligen reported stronger-than-expected Q3 earnings and revenue, providing FY2026 guidance, while analysts maintain a "Moderate Buy" rating with a consensus target price of $174.58.
Granahan Investment Management Trims Repligen Stake
Granahan Investment Management LLC has significantly reduced its stake in Repligen Corporation (NASDAQ:RGEN) by 48.3% during the third quarter, now holding 69,871 shares valued at $9.34 million. This move is detailed in a recent 13F filing and indicates a potential shift in market sentiment or a strategic decision by the institutional investor, which bears watching by other investors and analysts. Repligen is a biotechnology company focused on bioprocessing applications.
Fred Alger Management LLC Boosts Position in Repligen Corporation $RGEN
Fred Alger Management LLC increased its stake in Repligen Corporation by 19.7%, now owning 358,422 shares valued at approximately $47.9 million. Despite recent price target reductions by brokerages, the biotechnology company holds a "Moderate Buy" consensus rating and achieved a Q4 earnings beat with $0.49 EPS on $197.9 million revenue, exceeding analyst expectations. Repligen's FY2026 EPS guidance is set at $1.930-$2.010, though it currently trades at a high P/E ratio of 134.35.
Repligen Shares Purchased by Geneva Capital Management
Geneva Capital Management LLC has significantly increased its stake in Repligen Corporation (NASDAQ:RGEN) by 22.4% in the third quarter of 2026, boosting its holdings to approximately 596,768 shares. This makes Geneva Capital one of Repligen's largest shareholders, signaling strong confidence in the biotechnology company's growth prospects. Repligen is a key supplier of bioproduction consumables, crucial for the development and manufacturing of biopharmaceuticals.
Biological Product IgG Purification Medium Market Is Going to Boom | Repligen Corporation • Agilent Technologies
The Biological Product IgG Purification Medium Market is projected to see substantial growth from 2026 to 2033, driven by increasing demand and innovation. A new report by Coherent Market Insights provides a deep dive into market trends, competitive landscapes, and growth opportunities, offering essential insights for industry leaders. Key players include Thermo Fisher Scientific, Merck KGaA, and Repligen Corporation.
Repligen Corporation $RGEN Shares Purchased by Geneva Capital Management LLC
Geneva Capital Management LLC significantly increased its stake in Repligen Corporation (RGEN) by 22.4% in Q3, now holding 596,768 shares valued at approximately $79.8 million. The biotechnology company recently exceeded earnings expectations, reporting Q3 EPS of $0.49 and revenue of $197.9 million, while analysts have a "Moderate Buy" consensus rating with a target price of $174.58.
Schroder Investment Management Group Purchases 254,212 Shares of Repligen Corporation $RGEN
Schroder Investment Management Group significantly increased its stake in Repligen Corporation (NASDAQ:RGEN) by 123.2% in the third quarter, acquiring 254,212 additional shares to own a total of 460,609 shares valued at $61.57 million. This move highlights continued institutional interest in Repligen, with hedge funds and other institutional investors now owning 97.64% of the stock. Despite mixed analyst sentiment, Repligen has shown strong financial performance, beating quarterly expectations and projecting optimistic FY2026 guidance.
(RGEN) Risk Channels and Responsive Allocation
This article provides an analysis of Repligen Corporation (NASDAQ: RGEN), highlighting weak near and mid-term sentiment but a strong long-term outlook. It details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, and offers access to real-time signals and customized risk models.
Reassessing Repligen (RGEN) Valuation After Healthcare Jobs Shock And Margin Concerns
Repligen (RGEN) stock has faced pressure following a weaker February jobs report impacting healthcare stocks, despite reporting positive revenue and net income for Q4 and full year 2025. While analysts see fair value at $190.89, suggesting it's undervalued, the company's high P/E ratio of 138x compared to industry averages raises concerns about valuation risk, especially with recent softness in biotech funding and gene therapy demand. The article suggests investors should conduct their own due diligence, considering both the optimistic growth narrative and potential risks.
Reassessing Repligen (RGEN) Valuation After Healthcare Jobs Shock And Margin Concerns
Repligen (RGEN) is facing pressure after a weak February jobs report impacted healthcare stocks, despite reporting positive revenue and net income for Q4 and full-year 2025. While a popular valuation narrative suggests the stock is undervalued at $190.89 compared to its current $119.99, its high P/E ratio of 138x, significantly higher than the industry average, indicates potential valuation risk. Investors are urged to examine the numbers carefully despite mixed sentiment regarding the company's future growth and valuation.
Are Repligen's (RGEN) Stronger Earnings Masking Deeper Pressure On Its High-Margin Growth Story?
Repligen (RGEN) recently reported improved Q4 and full-year 2025 earnings, with a return to profitability and positive EPS. However, the article highlights concerns about the company's declining operating margins and reduced return on invested capital, suggesting these factors may overshadow the stronger headline figures. The investment narrative hinges on recovery in biotech orders, but challenges like scale disadvantages and margin pressure could limit growth payoff.
Repligen Corporation to Present at Upcoming March Conferences
Repligen Corporation announced its participation in three upcoming investor conferences in March: the Leerink Global Healthcare Conference, the Barclays 28th Annual Global Healthcare Conference, and the 2026 KeyBanc Virtual Healthcare Forum. Company executives, including CFO Jason Garland and CEO Olivier Loeillot, will participate in analyst-led discussions. Live webcasts of two presentations will be available on Repligen's Investor Relations website.
Repligen Corporation to Present at Upcoming March Conferences
Repligen Corporation (NASDAQ:RGEN) announced its participation in three investor conferences in March 2026: the Leerink Global Healthcare Conference, the Barclays 28th Annual Global Healthcare Conference, and the 2026 KeyBanc Virtual Healthcare Forum. CFO Jason Garland and CEO Olivier Loeillot will represent the company and participate in analyst-led discussions. Webcasts of the Leerink and KeyBanc presentations will be available on Repligen's Investor Relations website.
Bioprocessing firm Repligen fields CEO, CFO at three March investor conferences
Repligen Corporation (NASDAQ: RGEN) announced its participation in three investor conferences in March 2026: Leerink Global Healthcare, Barclays Global Healthcare, and KeyBanc Virtual Healthcare Forum. CFO Jason Garland and CEO Olivier Loeillot will represent the company, participating in analyst-led discussions. Webcasts of the Leerink and KeyBanc presentations will be available for replay on Repligen's investor relations website, providing investors with insight into the company's financial performance and strategic direction.
Repligen Corporation to Present at Upcoming March Conferences
Repligen Corporation (NASDAQ:RGEN), a life sciences company specializing in bioprocessing technology, announced its participation in three upcoming investor conferences in March. The announcement was made from Waltham, Mass., on March 5, 2026. Further details are available on globenewswire.com.
Repligen Corporation $RGEN Shares Sold by TD Asset Management Inc
TD Asset Management Inc. significantly reduced its stake in Repligen Corporation (NASDAQ:RGEN) by 66.4% in the third quarter, selling 52,596 shares. Despite this, Repligen exceeded quarterly earnings and revenue estimates and provided positive FY2026 guidance, leading to a consensus "Moderate Buy" rating among analysts. Various other institutional investors, however, increased their positions in the biotechnology company.
Repligen Corporation $RGEN Shares Acquired by Teachers Retirement System of The State of Kentucky
Teachers Retirement System of The State of Kentucky significantly increased its stake in Repligen Corporation (NASDAQ:RGEN) by 678.3% in Q3, now owning 121,398 shares valued at $16.23 million. Repligen surpassed earnings and revenue expectations in its recent quarter, reporting $0.49 EPS and $197.91 million in revenue, and provided optimistic FY2026 guidance. Analysts currently give Repligen a "Moderate Buy" rating with an average target price of $174.58.
Repligen Corporation to Present at Upcoming March Conferences
Repligen Corporation announced its participation in three upcoming investor conferences in March 2026: the Leerink Global Healthcare Conference, the Barclays 28th Annual Global Healthcare Conference, and the 2026 KeyBanc Virtual Healthcare Forum. Company executives Jason Garland and Olivier Loeillot will partake in analyst-led discussions. Webcasts of the Leerink and KeyBanc presentations will be available on Repligen's Investor Relations website.
Segall Bryant & Hamill LLC Cuts Position in Repligen Corporation $RGEN
Segall Bryant & Hamill LLC reduced its stake in Repligen Corporation by 6.2%, though institutional ownership overall remains very high at 97.64%. Despite some analysts slightly lowering price targets, the consensus rating for Repligen remains a "Moderate Buy." The biotechnology company recently surpassed quarterly earnings estimates and provided optimistic FY2026 EPS guidance, even as its stock trades at a high P/E ratio.
Repligen Stock Review 2026: Profitability Concerns Amid High Valuation - News and Statistics
A recent analysis highlights concerns regarding Repligen Corporation (RGEN) stock, despite its performance closely mirroring general market trends. The company faces criticism for its modest revenue scale, a significant decline in its adjusted operating margin over five years, and a decrease in return on invested capital. These profitability and scale issues, coupled with a high forward price-to-earnings valuation, suggest that other investment opportunities might offer stronger fundamental characteristics.
RGEN SEC Filings - Repligen 10-K, 10-Q, 8-K Forms
This page serves as a comprehensive resource for Repligen (RGEN) SEC filings, including annual 10-K reports, quarterly 10-Q earnings, 8-K material events, and insider trading forms. It provides detailed insight into the company's financial performance, governance, and significant corporate events. The platform also offers AI-powered summaries to help investors quickly identify key financial trends and disclosures for Repligen, a global life sciences company focused on bioprocessing technologies.
